The board of directors of SSY Group Limited announced that the Group's Norepinephrine bitartrate has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Norepinephrine bitartrate is an adrenergic receptors agonist, which is mainly used clinically in anti-shock by causing extreme contraction of blood vessels to increase blood pressure and coronary blood flow as well as by strengthening myocardial contraction and increasing cardiac output.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.78 HKD | +0.21% | +0.63% | -3.24% |
Apr. 23 | SSY Group Get Production, Registration Approval for Pneumonia Drug from Chinese Regulator | MT |
Apr. 16 | SSY Group Logs Nearly 15% Boost in Q1 Profit | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.24% | 1.81B | |
+33.59% | 664B | |
+29.29% | 567B | |
-7.50% | 354B | |
+18.42% | 330B | |
+4.54% | 286B | |
+13.79% | 234B | |
+4.93% | 199B | |
-9.78% | 196B | |
-4.67% | 148B |
- Stock Market
- Equities
- 2005 Stock
- News SSY Group Limited
- SSY Group Limited Announces its Norepinephrine Bitartrate Obtains the Approval for Registration from the National Medical Products Administration of China to Become a Bulk Drug for the Preparations on the Market